Business Context and Reporting Period
This Form 6-K filing by Morria Biopharmaceuticals Plc (now Celsus Therapeutics) is dated March 5, 2013. The filing announces the appointment of Gur Roshwalb, MD, as Chief Executive Officer and the approval of a corporate name change to Celsus Therapeutics by the Board of Directors, pending shareholder ratification at the June 2013 Annual General Meeting.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on executive compensation and corporate governance changes.
Material Changes
- Executive Leadership: Appointment of Dr. Gur Roshwalb as CEO, effective March 4, 2013.
- Corporate Identity: Trade name changed from Morria Biopharmaceuticals Plc to Celsus Therapeutics.
- Compensation Structure: Implementation of a new employment agreement with specific salary, equity, and bonus terms for the new CEO.
Guidance, Outlook, and Management Commentary
The filing details the terms of Dr. Roshwalb's employment agreement:
- Base Salary: Annualized salary of $350,000, subject to annual review.
- Equity Grant: Option to purchase 560,000 Ordinary Shares exercisable at the greater of $2.00 per share or fair market value on the grant date. Vesting occurs at 25% annually over four years, with full acceleration upon a change of control.
- Performance Bonus: Eligibility for an annual cash bonus of up to 33% of base salary based on clinical and business milestones.
- Financing Milestone: An additional option for 100,000 shares will be granted upon the closing of a financing of at least $15,000,000.
- Termination Provisions: In the event of termination without cause, the CEO is entitled to 12 months of base salary and 12 months of COBRA coverage.
- Covenants: Includes a six-month post-employment non-compete clause and standard confidentiality and IP assignment provisions.
Investor Verification Checklist
- Verify the shareholder ratification of the name change to Celsus Therapeutics at the June 2013 Annual General Meeting.
- Monitor the company's progress toward the $15,000,000 financing milestone required for the additional equity grant.
- Review the specific clinical and business milestones established by the Board for the annual performance bonus.
- Confirm the exact grant date and fair market value used to calculate the exercise price for the initial 560,000 share option.